Postsorafenib systemic treatments for hepatocellular carcinoma: questions and opportunities after the regorafenib trial.
暂无分享,去创建一个
G. Brandi | F. Tovoli | M. Pantaleo | G. Biasco | G. Frega | A. Palloni | M. A. Barbera | I. Garajová | S. D. Lorenzo